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Summary The aim of this study was to investigate the predictive value of an oxidative stress,
C-reactive protein (CRP) and N-terminal probrain natriuretic peptide (NT-proBNP) biomarkers
in acute myocardial infarction (AMI). The study population contained 100 patients with AMI
and 40 healthy subjects. Malondialdehyde (MDA) was measured as thiobarbituric acid
reactive substances. Total antioxidant status (TAC) was assayed with colorimetric method.
CRP and NT-proBNP was quantitated by immunoassay. MDA, CRP and NT-proBNP levels
were found significantly high in patients with AMI as compared to healthy controls (p<0.01).
Patients were divided into six groups based on the presence of disease history before AMI. In
patients with non-disease before AMI. MDA, CRP and NT-proBNP levels were lowest among
the patient groups. MDA levels in patients with hyperlipidemia/ diabetes/renal disease were
higher than the other groups. TAC levels in patients with hypertension were lower than as
compared to healthy controls (p<0.05). CRP levels in hypertension + hyperlipidemia patients
and NT-proBNP levels in cardiovascular + hypertension patients were found high as
compared to other patient groups. It is concluded that serum levels of MDA, CRP and NT-
proBNP were significantly increased in patients with AMI and these markers were strongly
predictive in AMI.
Key Words: oxidative stress, C-reactive protein, N-terminal probrain natriuretic peptide, acute
myocardial infarction
Introduction
Acute myocardial infarction (AMI) is one of the major
causes of mortality and morbidity in the world. The most
common cause of an AMI is atherosclerotic coronary artery
disease (CAD) with erosion or rupture of a plaque causing
transient, partial or complete arterial occlusion. Heart can
not continue to function without adequate blood flow, and if
it is severely compromised, death is inevitable. Several risk
factors for coronary heart disease have been well documented,
including hypertension, hyperlipidemia, diabetes, a positive
family story, smoking, obesity and inactivity [1]. However,
these factors explain only part of attributable cardivascular
disease. Evidence suggests that reactive oxygen species
(ROS) may play important roles in the pathogenesis in
myocardial infarction [2]. Following ischemia, ROS are
produced during reperfusion phase [3, 4]. ROS are capable
of reacting with unsaturated lipids and of initiating the self-
perpetuating chain reactions of lipid peroxidation in the
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membranes [5, 6]. Free radicals can also cause oxidation of
sulphydryl groups in proteins and strand scission in nucleic
acids is also possible [7]. Myocardial antioxidants inhibit or
delay the oxidative damage to subcellular proteins, carbo-
hydrates, lipids and DNA. There is evidence that anti-
oxidants can protect against free radical protection which
is responsible for reperfusion-induced damage and lipid
peroxidation, and may thereby inhibit thrombosis, myocardial
damage and arrhythmias during AMI [8]. Total antioxidant
capacity (TAC) is a critical tool for assessing redox status
[9]. The TAC or related antioxidants may play an important
role in protecting the organism from free-radicals-mediated
damage [10]. The role that such compounds play in AMI
development is important, since their presence may decrease
the damage resulting from blood ROS during reperfusion.
A growing body of evidence supports the concept that
local and systemic inflammation play a role in the initiation and
progression of atherosclerosis and its complications [11–13].
Inflammatory cells and mediators contribute to destabilizing
the protective fibrous cap on atherosclerotic plaques and have
been implicated in the pathogenesis of myocardial injury. C-
reactive protein (CRP) is an acute-phase reactant marker for
underlying systemic inflammation. CRP has been reported
to be elevated in patients with MI [14]. N-terminal probrain
natriuretic peptide (NT-proBNP) as an another new biomarker
for myocardial injury, is neurohormone synthesized primarily
in atrial or ventricular myocardium and is released from cardiac
myocytes in response to ventricular wall stress, ischemia or
infarction. NT-proBNP is important prognostic indicator in
congestive heart failure and acute coronary syndrome [15].
In this study, we compared lipid peroxidation, total anti-
oxidant capacity, CRP and NT-proBNP levels between
different risk groups in patients with acute myocardial
infarction. We examined the effects of sex, age, body mass
index, smoking habit, physical activity, dietary habit and
family history on measured parameters.
Materials and Methods
Chemicals
6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
(Trolox) and potassium persulphate, 2,2'-azino-bis(3-ethylbenz-
thiazoline-6-sulphonic acid) diammonium salt (ABTS),
sodium chloride, potassium chloride, potassium persulphate,
trichloroacetic acid and 1,1,3,3-tetraethoxypropane were
purchased form Sigma-Aldrich Co. (St. Louis, MO); sodium
dihydrogen orthophosphate dihydrate, disodium hydrogen
orthophosphate 12-hydrate, 2-thiobarbituric acid were
purchased from Merck & Co., Inc (West Point, PA).
Patients
This study was carried out in 140 subjects admitted to the
hospital for suspected AMI. Of these, 100 (79 men and 21
women) (mean age 62.17 ± 1.11 years) had evidence of
AMI. The other 40 subjects (29 men and 11 women)
(57.80 ± 1.11 years) were studied as controls. The diagnosis
of AMI was based on a history of prolonged ischemic chest
pain, characteristic electrocardiogram (ECG) changes and
elevated creatine kinase isoenzyme MB (CK-MB) and troponin
T within 12 h after the onset of pain. The patients with AMI
were divided into the following six groups according to disease
before AMI as hypertension group (n = 17), cardiovascular
disease group (n = 9), cardiovascular disease + hypertension
group (n = 28), hypertension + hyperlipidemia group (n = 13),
other disease (hyperlipidemia or diabetes or renal disease
group) (n = 11) and non-disease group (n = 22). Hyper-
tension was defined as a diastolic blood pressure≧90 mm
Hg, systolic blood pressure≧140 mm Hg, or self-reported
use of an antihypertensive drug. Cardiovascular disease was
diagnosed angiography, ECG, sintigraphy and effort test, or
self-reported use of a β-blocker, angiotensin I converting
enzyme (ACE) inhibitor and/or diuretic drug. The patients
who had total cholesterol level of>220 mg/dL or triglycerides
concentration>200 mg/dL, or receiving lipid lowering drugs
were defined as having hyperlipidemia. Diabetes mellitus
was diagnosed if the fasting plasma glucose concentration
was≧126 mg/dL or if the patient was treated with insulin or
oral hypoglycemic agents. Renal disease was defined as
estimated glomerular filtration rate<60 mL/min per 1.73 m2.
Patients with infection, inflammatory diseases, malignancy,
congenital malformations of the heart or vessels or history of
AMI were excluded. Normal subjects were chosen from
the same age group and had free from diabetes mellitus
and other chronic disease. No subject (patients or controls)
was taking antioxidant or vitamin supplements, probucol,
allopurinol, quinidine, disopyramide, or other drugs known
as affecting serum lipid peroxidation and and TAC values.
Oral consent was obtained from the patients’ relatives and
normal subjects, prior to study.
Sample collection
Study samples were collected from AMI subjects were
drawn soon after admission before starting any medication.
Venous blood was collected in the supine position for
analysis of malondialdehyde (MDA), TAC, CRP, NT-
proBNP, troponin T (TnT), CK-MB and lipid profile.
Clotted blood was centrifuged at 4°C, and the serum samples
were used for assays on the same day or frozen at −70°C
until being analyzed.
Serum malondialdehyde levels were determined with the
spectrophotometric method [16]. 100 µl serum was mixed
with 1000 µl 0.67% thiobarbituric acid (TBA) and 500 µl
of 20% tricloroacetic acid. The mixture was incubated at
100°C for 20 min. After cooling, the mixture was centrifuged
at 12000 g for 5 minutes and the absorbance was measured.
Serum TAC levels were determined according to ABTSS. Kasap et al.
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radical cation (ABTS+) decolorization assay [17]. ABTS
radical cation (ABTS+) was produced by reacting 7 mM
ABTS solution with 2,45 mM potassium persulfate (final
concentration) with a ratio of 1:0.5 and allowing the mixture
to stand in the dark at room temperature for 12 – 16 h before
use. ABTS+ solution was diluted with PBS, pH 7.4, to an
absorbance of 0.700 (±0.020) at 734 nm and 30°C. After
addition of 1.0 ml of diluted ABTS+ solution to 10 µl serum
or Trolox standarts in PBS the absorbance reading was taken
at 30°C exactly 6 minutes after initial mixing. % inihibition
values of samples and standarts are calculated and TAC
levels are calculated from the calibration graphic.
Determination of hs-CRP level was measured by the
nephelometric method on the basis of particle-bound goat
antihuman CRP (Beckman Instruments, Inc, Fullerton, CA)
and expressed as mg/dL. Serum NT-proBNP levels were
measured by automated immuno-assay (Elecsys pro BNP,
Roche Diagnostics, Mannheim, Germany). The test principle
includes using two polyclonal antibodies directed against N-
terminal proBNP; epitope 1:amino acid 1-21 and epitope
2:amino acid 39-50. The results are calibrated against a
synthetic NT-proBNP (amino acid 1-76). Both cardiac TnT
and CK-MB mass were measured with highly specific
monoclonal antibodies in a sensitive chemiluminescence
assay, with an Elecsys 2010 instrument (Roche Diagnostics,
Mannheim, Germany). Total cholesterol, triglycerides, LDL-
cholesterol, VLDL-cholesterol and HDL-cholesterol were
analyzed enzymatically.
Data analysis
The data for biochemical analysis were expressed as
mean ± SE. Student’s t test was applied to determine the
significance of biochemical parameters among two groups.
One-way analysis of variance (ANOVA) and Duncan test
were performed for measures of more than two groups.
Pearson correlation coefficients were calculated for relation-
ship between measured parameters. p value of <0.05 was
considered as significant. Data were analyzed using the
statistical package program SPSS 13.0.
Results
The baseline characteristics of the study population are
shown Table 1. As expected, the patients had higher total
Table 1. Demographic characteristics of the study group
AMI (n = 100) Controls (n = 40)
Males/females 79/21 29/11
Age (mean ± SE), years 62.17 ± 1.11 57.80 ± 1.11
Body mass index (mean ± SE), kg/m2 27.05 ± 0.29 24.69 ± 0.25
Risk factors (%)
Hypertension 17 —
Cardiovascular disease 9 —
Cardiovascular disease + hypertension 28 —
Hypertension + hyperlipidemia 13 —
Other (Hyperlipidemia/diabetes/renal disease) 11 —
Non-disease 22 —
Obesity 15 —
Family history 51 20
Smoking status
Current smoker 45 12.5
Ex-smoker 40 42.5
Non-smoker 15 45
Physical activity 16 40
Dietary habits
Olive oil 27 37.5
Olive oil + margarine 73 62.5
Total cholesterol (mean ± SE), mg/dl 175.23 ± 4.83a 154.20 ± 4.10
HDL-cholesterol (mean ± SE), mg/dl 41.80 ± 1.15a 48.85 ± 1.37
LDL-cholesterol (mean ± SE), mg/dl 107.02 ± 3.90a 76.65 ± 3.84
VLDL-cholesterol (mean ± SE), mg/dl 24.72 ± 1.40 28.70 ± 1.00
Triglyceride (mean ± SE), mg/dl 125.77 ± 7.25 134.37 ± 4.18
asignificant difference from control group (p<0.01).Cardiac Biomarkers in Myocardial Infarction
Vol. 41, No. 1, 2007
53
cholesterol and LDL-cholesterol but lower HDL-cholesterol
levels than the healthy controls (p<0.01, p<0.01, p<0.01,
respectively). There was no difference in VLDL-cholesterol
and triglyceride levels between the patients and the healthy
controls.
The mean MDA concentration in control group was found
2.68 ± 0.14 nmol/ml. In the total patient group, the mean
was found 4.53 ± 0.22 nmol/ml, which was significantly
elevated over the controls (p<0.01). When patients were
divided into six groups according to disease before AMI, the
highest MDA levels were found in hyperlipidemia/diabetes/
renal group (5.72 ± 0.68 nmol/ml), the lowest MDA levels
in non-disease group (3.71 ± 0.47 nmol/ml). In non-disease
group, MDA levels were found low as compared to
hyperlipidemia/diabetes/renal group (p<0.05), but hig as
compared to control group (p<0.05). MDA levels in other
disease groups were found significantly higher as compared
to controls (p<0.01) (Table 2).
The mean concentration of TAC in all patients with AMI
was 1.27 ± 0.02 µmol/l as compared to 1.33 ± 0.02 µmol/l
in controls (Table 2). This difference was not significant, as
measured by ANOVA (p>0.05). When AMI patients were
divided into six group, it was found that patients with hyper-
tension showed significantly lower TAC levels than patients
with hyperlipidemia/diabetes/renal disease (1.19 ± 0.04 µmol/l,
1.39 ± 0.08 µmol/l, respectively) (p<0.05). The TAC levels
in patients with hypertension was also lower than control
group (p<0.01).
The patients with AMI had significantly higher CRP levels
(1.57 ± 0.07 mg/dl) than control group (0.58 ± 0.03 mg/dl)
(p<0.01). When total patients were divided into six groups
according to disease before AMI, all patient groups were
higher than control group (p<0.01) (Table 2). The CRP levels
in patients with non-disease group (1.15 ± 0.13 mg/dl) were
lower than the other patient groups (cardiovascular 1.71 ±
0.15 mg/dl; cardivascular + hypertension 1.73 ± 0.11 mg/dl;
hypertension + hyperlipidemia 1.98 ± 0.19 mg/dl; hyper-
lipidemia/diabetes/renal disease 1.81 ± 0.17 mg/dl) (p<0.05;
p<0.01; p<0.01; p<0.01, respectively) except patients with
hypertension (1.33 ± 0.18 mg/dl) (p>0.05). Cardiovascular
+ hypertension and hypertension + hyperlipidemia patients
showed significantly high CRP levels when compared
hypertension group (p<0.05; p<0.05, respectively).
NT-proBNP level was also found significantly high in
total AMI patients (1432.17 ± 140.64 pg/ml) as compared to
controls (93.23 ± 3.25 pg/ml). AMI patients were divided
into sub groups according to disease before AMI, the lowest
NT-proBNP levels were in patients with non-disease group
(818.23 ± 210.91 pg/ml) as compared to other patient groups
and there were a significant differences between non-disease
Table 2. Comparison of MDA, TAC, CRP, NT-proBNP, TnT and CK-MB in patient groups and control group
MDA 
(nmol/ml)
TAC 
(µmol/l)
CRP 
(mg/dl)
NT-proBNP 
(pg/ml)
TnT 
(ng/ml)
CK-MB 
(U/l)
Hypertension group 
(n =1 7 )
4.67 ± 0.40a 1.19 ± 0.04a 1.33 ± 0.18a 847.98 ± 140.90a 1.32 ± 0.37a 126.06 ± 34.71a
Cardiovascular 
group (n =9 )
4.08 ± 0.54a 1.22 ± 0.07 1.71 ± 0.15a 2216.16 ± 668.48a,i 1.47 ± 0.44a 155.00 ± 45.23a
Cardiovascular +
hypertension group 
(n =2 8 )
4.90 ± 0.49a 1.27 ± 0.04 1.73 ± 0.11a,i 1957.86 ± 255.19a,h 1.28 ± 0.29a 115.43 ± 17.80a
Hypertension +
hyperlipidemia group 
(n =1 3 )
4.28 ± 0.64a 1.29 ± 0.07 1.98 ± 0.19a,i 1681.87 ± 569.82a 1.21 ± 0.33a 109.23 ± 20.42a
Hyperlipidemia / 
diabetes / renal 
group (n =1 1 )
5.72 ± 0.68a 1.39 ± 0.08i 1.81 ± 0.17a 1288.29 ± 292.61a 0.95 ± 0.35a 183.55 ± 48.39a
Non-disease group 
(n =2 2 )
3.71 ± 0.47b,g 1.27 ± 0.04 1.15 ± 0.13a,c,d,e,f 818.23 ± 210.91a,c,d 0.88 ± 0.30a 84.59 ± 14.23a,g
Total patients 
(n =1 0 0 )
4.53 ± 0.22a 1.27 ± 0.02 1.57 ± 0.07a 1432.17 ± 140.64a 1.17 ± 0.14a 120.70 ± 11.08a
Controls (n = 40) 2.68 ± 0.14 1.33 ± 0.02 0.58 ± 0.03 93.23 ± 3.25 0.01 ± 0.00 12.55 ± 0.82
asignificant difference from control group (p<0.01),  bsignificant difference from control group (p<0.05),  csignificant difference from
cardiovascular group (p<0.05), dsignificant difference from cardiovascular + hypertension group (p<0.01), esignificant difference from
hypertension + hyperlipidemia group (p<0.01), fsignificant difference from hyperlipidemia + diabetes + renal group (p<0.01), gsignificant
difference from hyperlipidemia + diabetes + renal group (p<0.05), hsignificant difference from hypertension group (p<0.01), isignificant
difference from hypertension group (p<0.05).S. Kasap et al.
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group and cardiovascular group (2216.16 ± 668.48 pg/ml)
and cardiovascular + hypertension group (1957.86 ± 255.19
pg/ml) (p<0.05; p<0.01, respectively). A significant differences
were found between patients with hypertension (847.98 ±
140.90 pg/ml) and cardiovascular group (2216.16 ± 668.48
pg/ml) (p<0.05), hypertension group and cardiovascular
+ hypertension group (1957.86 ± 255.19 pg/ml) (p<0.01)
(Table 2).
Serum TnT and CK-MB levels were also significantly
high in total AMI patients (1.17 ± 0.14 ng/ml; 120.70
± 11.08 U/l) as compared to controls (0.01 ± 0.00 ng/ml;
12.55 ± 0.82 U/l) (p<0.01;  p<0.01, respectively). When
patients were divided into six groups according to disease
before AMI, the highest CK-MB levels were found in
hyperlipidemia/diabetes/renal group (183.55 ± 48.39 U/l), the
lowest CK-MB levels in non-disease group (84.59 ±
14.23 U/l) and a significant difference was found between
these groups (p<0.05) (Table 2).
Serum TnT values in patients with AMI showed positive
correlations with NT-proBNP (r = 0.28, p<0.01), CK-MB
(r =0 . 3 1 ,  p<0.01) and MDA (r =0 . 2 3 ,  p<0.01) (Table 3).
There were inverse correlations between HDL-cholesterol
and CRP (r = −0.22,  p<0.05), HDL-cholesterol and NT-
proBNP (r = 0.21,  p<0.05), total cholesterol and NT-
proBNP (r = 0.22, p<0.05) in total patients. Another inverse
correlation was also found in control group between HDL-
cholesterol and TAC (r = −0.54,  p<0.01) (Table 3). No
significant differences could be identified with regard to sex,
age, body mass index, obesity, family history, smoking
habit, physical activity, dietary habit and family history in
patients with AMI.
Discussion
Several experimental reports demonstrate that ischemia
followed by reperfusion elicit a cascade of proinflammatory
reactions that are known to lead to the production of ROS
[18], activation of the complement system [19], leukocyte
mediated injury of myocardial cells [20], and production of
cytokines [21]. There is a growing evidence that increased
free radical production and impaired antioxidant protection
are relevant to plaque activation. In addition to traditional
risk factors, oxidative stress has been regarded as one of the
most important contributors to the progression of athero-
sclerosis [22]. Increased lipid peroxidation is thought to be a
consequence of oxidative stress which occurs when the
dynamic balance between prooxidant and antioxidant
mechanism is impaired [23]. In ischemia, the ATP is drastically
reduced and is converted to hypoxanthine and then to uric
acid by xanthine oxidase upon reperfusion. During this
process, enormous amounts of superoxide radicals formed
which can simulate Haber-Weiss reaction for further generation
of ROS, initiating lipid peroxidation [24]. It has been
suggested that increased lipid peroxides levels in blood of
patients with AMI [25,  26]. We observed that increased
concentrations of MDA in the circulation of total AMI
patients indicating increased lipid peroxidation. Our results
are in accordance with previous reports [25–27]. In our
study, we observed MDA levels both total patients and each
patient group classified presence of disease before AMI, as
compared to control group. MDA levels in non-disease
group were lower than the other patient groups, and a
significant difference was only found between non-disease
group and hyperlipidemia/diabetes/renal group. In our
opinion, lipid peroxidation might be increased due to the
presence of systemic diseases including hyperlipidemia or
diabetes mellitus or renal disease in addition to myocardial
infarction.
Several antioxidant protective mechanisms exist against
free radical damage and constitute a primary defensive
system including vitamins such as vitamins C, E and β-
carotene and enzymatic defences [28–30]. It is known
that plasma antioxidant capacity decreases and oxidative/
antioxidative balance shifts to the oxidative side in patients
with CAD [31,  32]. Kharb and Singh [33] showed that
plasma vitamin E was significantly lower in AMI patients as
compared to healthy controls. Yao et al. [34] have reported
that decrease of the TAC value following AMI. Their data
indicated that the TAC value decreased continously, and
finally, it became stable. Similary, Senthil et al. found low
concentrations of vitamin C, vitamin E and β-carotene in the
circulation of patients with AMI may be due to increased
utilization to scavenge lipid peroxides. In contrast, Chamblee
et al. showed that TAC levels in AMI patients was not
Table 3. Pearson correlation coefficients between measured parameters in total patient and control groups
CRP NT-proBNP CK-MB MDA TAC
Total patients
TnT — 0.28** 0.31** 0.23** —
HDL-cholesterol −0.22* −0.21* — — —
Total-cholesterol — −0.22* — — —
Controls HDL-cholesterol — — — — −0.54**
*Correlation is significant for p<0.05
**Correlation is significant for p<0.01Cardiac Biomarkers in Myocardial Infarction
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different from the control population. In this study, TAC
levels were lower in total patients with AMI than in control
group, but this difference was not statistically significant.
However, in hypertensive-myocardial infarcts, TAC level was
less than that found in healthy controls and hyperlipidemia/
diabetes/renal group. It is not known why there is a decrease
in TAC levels in hypertension.
Inflammation plays a role in the development of athero-
sclerosis and coronary heart disease [35]. Elevated markers
of inflammation, in particular CRP, are associated with an
increased risk of future cardiovascular events in healthy
subjects, in patients with stable or unstable coronary artery
disease and acute myocardial infarction [36, 37]. Although
the prognostic value of CRP in patients with myocardial
infarction has not been tested in large studies, several data
indicate that CRP is an important marker of risk also in this
clinical setting [38,  39]. CRP has been reported to be
elevated during AMI [14, 40]. In this study, we observed
increased CRP levels in AMI patients as compared to
healthy controls. Moreover, CRP concentrations in each
patient group were found higher than the control group. We
have observed highest concentrations of CRP in patients
with hypertension + hyperlipidemia among the patient groups.
Elevated CRP levels were also observed in hyperlipidemia/
diabetes/renal group and cardiovascular + hypertension
group, respectively. We found an elevation of CRP levels in
cardiovascular + hypertension group and hypertension +
hyperlipidemia group as compared to hypertension group.
Hypertension plus cardiovascular disease or hyperlipidemia
seems to be responsible for the elevation of CRP levels.
Hypertension, diabetes mellitus, older age, extension of
necrosis area, previous AMI, and anterior site of AMI are
considered among the most important features leading to
heart failure during AMI [41,  42]. CRP concentration in
non-disease group was the lowest in the patient groups and a
significant differences were observed between the other
groups except patients with hypertension.
Natriuretic hormones are a family of vasoactive peptides
that act as balanced arterial and venous vasodilators and
they promote, as their name suggests, natriuresis and
diuresis. The ability to measure the circulating concentration
of these hormones has lead to an interest in using these
levels to enhance diagnostic and prognostic assessment
among patients with cardiovascular disease. Previous studies
have convincingly demonstrated that circulating levels of
NT–proBNP are increased in patients with AMI and predict
mortality [43, 44]. Sabatine et al. [45]. demonstrate that an
important link between the severity of an acute ischemic
insult and the circulating levels of BNP. In this study, we
observed increased NT-proBNP levels in patients with AMI
as compared to healthy population. NT-proBNP levels in
cardiovascular patient group were found highest among the
patient groups. Second group of sequence was cardivascular +
hypertension group according to increased levels of NT-
proBNP. A significant differences were found between
hypertension group and cardiovascular group, hypertension
group and cardiovascular + hypertension group. Similar
differences were observed between non-disease group and
cardiovascular group, non-disease group and cardiovascular +
hypertension group.
Troponins I and T are proteins of the troponin regulatory
complex involved in cardiac contractility. Both have very
high myocardial tissue specificity, are not detectable in the
blood of healthy persons and offer an improved sensitivity
and specificity for AMI versus a combination of ECG
and traditional biochemical markers. The cardiac-specific
troponins are highly sensitive and specific markers of
myocardial damage [46] and therefore cardiac troponins
are the preferred markers for the diagnosis of myocardial
infarction [47]. In this study, increased TnT levels were
found in patients with AMI as compared to healthy controls,
as expected. The highest TnT levels were observed in
cardiovascular group and the lowest TnT levels in non-
disease group among the patient groups.
CK and more particularly its isoenzyme CK-MB still have
a formal place in defining myocardial infarction. However
the current definition is not a particularly useful one because
studies have shown that, as currently defined, patients with
myocardial infarction and unstable angina have similar
outcomes [48, 49]. In this study, as expected, CK-MB levels
in patients with AMI were higher than healthy population.
We found an significant elevation of CK-MB in group of
hyperlipidemia/diabetes/renal disease. When the patient
groups were compared according to CK-MB levels, a
significant difference was found between hyperlipidemia/
diabetes/renal group and non-disease group.
Lipoproteins with higher concentrations of vitamin E are
more able to resist damage from oxidative stress [50]. Thus,
exposure and susceptibility of lipids to oxidation appear to
be important factors in the initiation and growth of athero-
sclerotic plaques. In this study, we found that elevated LDL
and decreased HDL levels in patients with AMI as compared
to healthy controls.
In conclusion, our study shows a significant increase in
MDA, CRP and NT-proBNP in the circulation of patients
with AMI. A significant decrease of TAC levels observe
only in AMI patients with hypertension. Therefore these
biomarkers may be useful diagnosis of patients with AMI. A
larger study with a sample size capable to detect differences
in clinical outcome is now warranted.
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